Ocular Therapeut (OCUL)

$8.41 +0.63 (8.10%)
Market Cap 1.69B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.11
Volume 6,357,080
Avg Vol 5,824,200
Day's Range N/A - N/A
Shares Out 217.69M
Stochastic %K 45%
Beta 0.90
Analysts Strong Sell
Price Target $24.08

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
15 Crosby Drive, Bedford, United States
diggs24
diggs24 Feb. 23 at 10:49 PM
$OCUL 😆
0 · Reply
Mmmm888
Mmmm888 Feb. 23 at 10:31 PM
$OCUL
0 · Reply
Mmmm888
Mmmm888 Feb. 23 at 10:30 PM
$OCUL This happened in less than 24 hours
1 · Reply
Dontknowwhatimdoing95
Dontknowwhatimdoing95 Feb. 23 at 10:08 PM
$OCUL if I see that sanofi article from january one more time I’m crashing out
1 · Reply
The_Scientist
The_Scientist Feb. 23 at 9:49 PM
$OCUL wake up every morning and tell yourself I am not a 🐏 🐑, because then you will make real money.
1 · Reply
XQuise
XQuise Feb. 23 at 9:38 PM
$OCUL So far so good... there's more to come in the long run 🤑
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:19 PM
$OCUL read and follow me
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:18 PM
$OCUL timing is everything …. purchased at the Lows . Didn’t even show up on the chart because it was intraday.
0 · Reply
RunnerSignals
RunnerSignals Feb. 23 at 9:16 PM
market warriors bounce back $NAK $USAR $CRML $OCUL $FRPT
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:15 PM
$OCUL follow me
0 · Reply
Latest News on OCUL
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:41 AM EST - 4 days ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Feb 17, 2026, 4:15 PM EST - 6 days ago

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

Feb 17, 2026, 7:08 AM EST - 6 days ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026, 5:00 PM EST - 10 days ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 17 days ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Feb 4, 2026, 7:30 AM EST - 19 days ago

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Dec 8, 2025, 12:59 PM EST - 2 months ago

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:16 PM EST - 3 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:05 AM EST - 3 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Nov 4, 2025, 7:00 AM EST - 3 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Oct 1, 2025, 4:22 AM EDT - 5 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 7:08 AM EDT - 5 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 30, 2025, 6:21 AM EDT - 5 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 5:05 PM EDT - 6 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Sep 7, 2025, 1:52 AM EDT - 6 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:33 PM EDT - 7 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 26, 2025, 1:54 PM EDT - 8 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 10 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 11, 2025, 2:49 PM EDT - 1 year ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 6, 2025, 11:15 AM EST - 1 year ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:16 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Ocular Is Now Thoroughly Derisked

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

diggs24
diggs24 Feb. 23 at 10:49 PM
$OCUL 😆
0 · Reply
Mmmm888
Mmmm888 Feb. 23 at 10:31 PM
$OCUL
0 · Reply
Mmmm888
Mmmm888 Feb. 23 at 10:30 PM
$OCUL This happened in less than 24 hours
1 · Reply
Dontknowwhatimdoing95
Dontknowwhatimdoing95 Feb. 23 at 10:08 PM
$OCUL if I see that sanofi article from january one more time I’m crashing out
1 · Reply
The_Scientist
The_Scientist Feb. 23 at 9:49 PM
$OCUL wake up every morning and tell yourself I am not a 🐏 🐑, because then you will make real money.
1 · Reply
XQuise
XQuise Feb. 23 at 9:38 PM
$OCUL So far so good... there's more to come in the long run 🤑
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:19 PM
$OCUL read and follow me
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:18 PM
$OCUL timing is everything …. purchased at the Lows . Didn’t even show up on the chart because it was intraday.
0 · Reply
RunnerSignals
RunnerSignals Feb. 23 at 9:16 PM
market warriors bounce back $NAK $USAR $CRML $OCUL $FRPT
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:15 PM
$OCUL follow me
0 · Reply
OptionFlowTrader
OptionFlowTrader Feb. 23 at 9:14 PM
$OCUL I knew there would be a bounce Follow me in our trades take a look at my screenshots today great day being bearish on my Microsoft puts
0 · Reply
Irish_lass
Irish_lass Feb. 23 at 9:12 PM
$OCUL Solid close, stay tuned for continuation.
0 · Reply
diegosan21
diegosan21 Feb. 23 at 9:08 PM
$OCUL always trust a biotech that has been punished far more than it deserved
0 · Reply
ProfitForever
ProfitForever Feb. 23 at 9:05 PM
$OCUL BOOM from 7.80 to 8.42.. now 9.00 is a target this week. Oversold with solid upside. GL Bulls!
0 · Reply
holdgold44
holdgold44 Feb. 23 at 8:56 PM
$OCUL the guy here who said we are all idiots before the data came out was spot on. We still are all idiots and nobody knows wtf they are talking about. The bears and the bulls and the analysts.
0 · Reply
Twobad31
Twobad31 Feb. 23 at 8:54 PM
$OCUL easy money made off that 5.47 entry.
1 · Reply
nopennys
nopennys Feb. 23 at 8:44 PM
$OCUL already has recovered by 3$ after they made it crash a few days ago! More buyers will come in anticipation to the event on 27th Feb!
0 · Reply
Herrm
Herrm Feb. 23 at 7:54 PM
$OCUL https://pharmaphorum.com/news/sanofi-linked-takeover-bid-ocular-therapeutix
1 · Reply
SilasBrookhaven
SilasBrookhaven Feb. 23 at 7:06 PM
$OCUL biotech under the radar tight range if volume expands breakout asymmetry
0 · Reply
YosemiteSam83
YosemiteSam83 Feb. 23 at 6:44 PM
$OCUL
0 · Reply
Lanaez
Lanaez Feb. 23 at 6:40 PM
$OCUL I don’t even know what the date is I’m off to a great start 🥴
0 · Reply
Lanaez
Lanaez Feb. 23 at 6:39 PM
$OCUL would love to see this push through the resistance and hold above $8.37. It could see $8.70 with some volume, maybe by tomorrow. Just my guess based on the 30 minute chart; take what I say w a grain of salt bc I talk out of my ass most of the time.
0 · Reply